Skip to main content


Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus

Fig. 1

a Brachial artery flow-mediated dilation (FMD) values and b reactive hyperaemia index (RHI) at inclusion in the study (day 0; white columns) and after 12 weeks of treatment (grey columns) in groups treated with empagliflozin 25 mg daily (EMPA), metformin 2000 mg daily (MET) or empagliflozin/metformin (EMPA/MET). *P < 0.05; **P < 0.01; ***P < 0.001 for comparison with initial values at the beginning of the treatment in separate groups

Back to article page